Paysign, Inc. Announces Record-Breaking Q3 2025 Financial Results

In Q3 2025, Paysign reported total revenues of $21.6 million, marking a 41.6% increase year-over-year. This surge in revenue is attributed primarily to the company's expanding pharma patient affordability business, which experienced astonishing growth of 141.9%. Adjusted EBITDA reached a record $5.0 million, reflecting a 78.1% increase, while net income rose by 54.2% to $2.2 million.

“Our revenue soared to $21.6 million, reflecting an outstanding year-over-year growth rate,” said Newcomer. “These results underscore the exceptional momentum and improving operational efficiencies driving our business forward.”

The pharma patient affordability sector was a standout performer, with revenues increasing by $4.65 million due to the addition of 39 new programs over the past year, resulting in 105 active programs by the end of the quarter. The company anticipates launching an additional 20-30 programs before year-end. Processed claims surged by over 60% compared to the previous year, contributing to a remarkable average quarterly revenue per program of $75,434, up from $49,599 in the same quarter last year.

On the plasma donation front, Paysign’s donor compensation business rebounded with a 12.4% increase year-over-year, bringing in an additional $1.42 million. The growth stemmed from the addition of 117 new plasma centers over the last year, although the company faced challenges due to a decline in donations and overall revenue per center. Despite a reduction of 12 centers in the latest quarter due to planned closures, the company ended the quarter with 595 active centers.

During the third quarter, Paysign launched a new 30,000-square-foot customer service contact center which quadrupled its support capacity. This strategic expansion positions Paysign to meet the increasing demand in its patient affordability business effectively.

As of September 30, 2025, Paysign's total cash balances decreased by $3.79 million from December 31, 2024, primarily due to payment timing on receivables and increased investments in infrastructure. Unrestricted cash stood at $7.53 million.

Looking ahead, Paysign has revised its full-year 2025 revenue estimates upward, now projecting total revenues between $80.5 million and $81.5 million, which represents a 38.7% year-over-year growth at the midpoint. The company expects its pharma patient affordability revenue to account for approximately 41% of total revenue, reflecting over 155% year-over-year growth.

CFO Jeff Baker stated, “Our operating margin improved significantly, reflecting the operating leverage inherent in our business model while making substantial investments to ensure ongoing success.”

Paysign, Inc. continues to demonstrate robust growth and operational efficiency, positioning itself as a leader in patient affordability and donor compensation solutions. With a strong foundation and strategic expansions, the company is well-prepared to capitalize on future growth opportunities within the life sciences sector.

A conference call to discuss these results will be held today at 5:00 p.m. Eastern time, providing further insights into the company's performance and future strategic direction.